Compare · NEON vs TMO
NEON vs TMO
Side-by-side comparison of Neonode Inc. (NEON) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- NEON operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.49B, about 6339.6x NEON ($27.5M).
- Over the past year, NEON is down 87.2% and TMO is up 11.5% - TMO leads by 98.6 points.
- TMO has hit the wire 6 times in the past 4 weeks while NEON has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 2 for NEON).
- Company
- Neonode Inc.
- Thermo Fisher Scientific Inc
- Price
- $1.64+0.00%
- $469.57+0.63%
- Market cap
- $27.5M
- $174.49B
- 1M return
- +20.15%
- -4.31%
- 1Y return
- -87.19%
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 6
- Recent ratings
- 2
- 25
Neonode Inc.
Neonode Inc., together with its subsidiaries, develops optical sensing solutions for contactless touch, touch, gesture sensing, and in-cabin monitoring in the United States, Japan, South Korea, China, and internationally. The company also licenses its technology to original equipment manufacturers (OEMs) and Tier 1 suppliers. In addition, it provides embedded sensors to OEMs, original design manufacturers, and Tier 1 suppliers. Further, the company sells Neonode branded sensor products, such as AirBar products through distributors. Additionally, it provides engineering consulting services. Neonode Inc. was incorporated in 1997 and is headquartered in Stockholm, Sweden.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest NEON
- Neonode Reports 2025 Financial Results
- SEC Form 10-K filed by Neonode Inc.
- Neonode Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Appointment of Marec Gasiun as Executive Vice President of Sales & Marketing at Neonode
- Neonode Reports Quarter Ended September 30, 2025 Financial Results
- SEC Form 10-Q filed by Neonode Inc.
- Neonode Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neonode downgraded by Ladenburg Thalmann with a new price target
- Neonode Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Neonode Announces Anticipated Financial Proceeds from Patent Lawsuit Settlement
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S